Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Maybe you should read this too:

MTOR INHIBITORS: FROM LYMPHANGIOLEIOMYOMATOSIS TO WHERE? October 2010

http://annonc.oxfordjournals.org/content/21/suppl_8/viii35.full.pdf

BTW, don't worry - I didn't write it. A sarcoma oncologist did, but you don't have to take his word for it.


And this, too:

AT THE CROSSROADS OF MOLECULAR PATHWAYS AND SARCOMA SUBTYPES

....This calls for a change in STS clinical trial design towards histological and/or molecular subtype-specific studies.